Strucvue Medical, Inc.

### Executive Summary Strucvue Medical, Inc., a Delaware corporation incorporated in 2026, has filed a Form D initial notice for a private placement of equity securities (Common Stock) under Rule 506(b), raising $100 as of the first sale date of May 11, 2026. The offering is limited to accredited investors with no general solicitation, and the issuer has declined to disclose its revenue range. The sole related person is CEO and Director Noam Seker Gafni, whose address in Irvine, CA differs from the company's Sacramento headquarters, suggesting a lean, early-stage operation. The minimal $100 raise indicates a symbolic or seed-stage capital infusion, likely for initial organizational expenses or to establish a regulatory filing presence. ### Investor Edge Investors should monitor for subsequent Form D amendments (D/A) that would indicate additional capital raises or changes in terms, which would signal genuine operational progress. The lack of a business description or use of proceeds in the filing limits actionable intelligence; any future public records (e.g., state business filings, patent applications) would be the next watchpoint. ### Sector capital positioning The 'Other Health Care' sector classification and the nominal $100 raise reflect a micro-cap, pre-revenue startup testing the regulatory filing process. This filing does not signal meaningful capital flow into health care but rather a foundational step for a very early-stage entity. The 2026 incorporation date and first sale within the same year underscore the nascent nature of the company. ### Convergence Signals No convergence signals are evident from this filing. There are no referenced patents, government contracts, or competitor activity. The filing is a standard initial notice with no amendment history, and the company has no previous names or public disclosures beyond this Form D. ### Key Takeaways - Strucvue Medical is a newly incorporated (2026) Delaware corporation raising only $100 in its first Reg D offering under Rule 506(b). - The sole executive officer and director is Noam Seker Gafni, who serves as CEO; no other investors or insiders are disclosed. - The filing is an initial notice (not an amendment), with no indication of a larger offering or business operations beyond the minimal capital raise. ### Risk Indicators & Flags The $100 raise is unusually low for a corporate entity, potentially indicating a test filing or placeholder. The company's revenue is undisclosed, and no business description is provided, raising uncertainty about its operational status. The offering is limited to accredited investors under Rule 506(b), which restricts general solicitation but allows up to 35 non-accredited investors; however, no investor count or non-accredited investor data is disclosed in the filing excerpt. ### Verification & References All facts are directly from the SEC EDGAR filing with accession number 000213778526000001. The CIK 0002137785, entity name, address, related person details, exemption (Rule 506(b)), and offering amount ($100) are verifiable via the SEC's EDGAR system. The company's incorporation year (2026) and jurisdiction (Delaware) are confirmed in the XML.